Folic acid is an important cofactor for the biosynthesis of a wide range of metabolites and is an essential component of the diet for higher eukaryotic organisms, including man. Prokaryotes and some lower eukaryotes can synthesize folic acid c k ~0 2~0 from pum-aminobenzoic acid (PABA) and GTP via a multi-step series of reactions, some of which are shown in Figure 1 [ 1-31. 7,8-Dihydroneopterin is formed via several steps from GTP, the first reaction being cataAbbreviations used: PABA, pnm-aminobenzoic acid; DH NA, dihydroneopterin aldolase; € IPPK, 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase); DHPPP, 6-pyrophosphomethyl-7,8-dihydroptcrin; DHPS, dihydroptcroate synthase; Dl IP, 6-hydroxymethyl-7,8-di hydropterin.
' '1'0 whom correspondence should be addressed. lysed by GTP cyclohydrolase (not shown in Figure 1 ). An aldolase step is carried out on 7,8-dihydroneopterin by the enzyme dihydroneopterin aldolase (DHNA), followed by a pyrophosphokinase step catalysed by 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK), using ATP. The product of this reaction, (DHPPP) , is then used as a substrate for dihydropteroate synthase (DHPS). DHPS (E.C. 2.5.1.15) catalyses the formation of a carbonnitrogen bond, joining the pterin moiety within DHPPP to PABA to form dihydropteroate and pyrophosphate. DHPS therefore sits at the conjunction of two biosynthetic pathways, one from GTP to folic acid and the other from chorismate, which ultimately forms PABA. In the final section of the pathway, dihydrofolate is formed by addition of glutamate to dihydropteroate, via dihydrofolate synthase, and is then used as the substrate for dihydrofolate reductase.
6-pyrophosphomethyl-7,8-dihydropterin
The fact that the folate biosynthesis enzymes are absent from man has made them an attractive target for the design of antimicrobial drugs. A good illustration of this rationale is the sulphonamides, which have been widely used in clinical practice for 60 years as antimicrobial and antiparasitic agents [4]. Sulphonamides act as analogues of PABA and are known to be specific inhibitors of folate biosynthesis [5-71. ( The structure of a simple sulphonamide, sulphanilamide, is shown in Figure 1 .) The introduction of sulphonamides in the late 1930s had a dramatic effect on the treatment of bacterial infections. For example, fatality rates in cases of meningococcal meningitis fell from over 80% to 20% largely as a result of their introduction [8] . The use of sulphonamides to treat bacterial infections declined rapidly after the introduction of penicillin, but they are still in clinical use for the treatment of non-bacterial infections. Sulphamethoxazole is used as a first-line treatment for infection by Pneumoqlstis mi-inii, a common infection in patients with AIDS [9] . In these cases sulphamethoxazole is administered in conjunction with the dihydrofolate reductase inhibitor trimethoprim, illustrating how two specific inhibitors of folate metabolism can act in concert. This approach is also used in treating the malaria parasite Plusmochm fiilcipui-um, through the use of Fansidar"', which is a combination of the dihydrofolate reductase inhibitor pyrimethamine and the sulphonamide sulfadoxine [ 101. The value of antifolate chemotherapy in the treatment of a wide range of human pathogens is therefore beyond dispute.
Studies of the inhibition of I:'scAeric.hiu coli DHPS by sulphonamides have found that they act as alternative substrates for DHPS both in vitro and in vivo, forming the corresponding 7,8-dihydropterin-sulphonamide as product [11, 12] . Diffusion studies showed that the 7,8-dihydropterin-sulphonamide derivatives diffused readily from the microbial cell and no [13-191. It is interesting to note that DHPS from some eukaryotic sources occurs as a bifunctional complex with HPPK; this is the case for I'. fak-$arum, 7'. gondii and l'isum sativzm [15, 19, 20] . In P. carinii, DHNA, HPPK and DHPS all occur on one polypeptide chain [ 16, 211 . Widespread resistance to sulphonamides has been documented in many organisms and several studies have been published that relate a sulphonamide resistance phenotype to specific mutations within the dhps gene. Lopez et al. [22] identified a 6-bp insertion in the SuVI dhps gene that appeared to correlate with sulphonamide resistance in S. pneumoniue. More recently, this work has been extended by Maskell et al. [23] , who compared the S U M gene sequences from 12 clinical isolates of S. pneuinoniue and found that 3-or 6-bp insertions between Arg-58 and Tyr-63 accounted for the resistance phenotype. In other cases resistance seems to occur by substitution of amino acids at certain positions. For example, the increasing resistance to sulphonamides in the malaria parasite has been shown to correlate with amino acid substitutions in at least one of five different positions within the I'lasmodium dhps gene [ 10,151. Sulphonamide resistance phenotypes in the meningitis pathogen *Y. ineningitidis appear to have arisen through horizontal gene transfer from other Neisseriu species, forming mosaic gene structures [18, 24] . Some meningococcal strains appear to acquire resistance by insertion of a dipeptide into the dhps gene sequence although, interestingly, this does not occur at the same position as in the streptococcal enzyme. dhps genes from other sulphonamideresistant meningococcal strains contain amino acid substitutions at positions 31, 84 and 194. The relative importance of each of these mutations has been evaluated by site-directed mutagenesis and study of the kinetic properties of the mutant enzymes [25] . It was found that mutation from a sensitive to a resistant form of the enzyme increases the K,,, for PABA to some extent, but appears to have a greater effect on the K , for sulphonamide.
CH(OH).CH(OH).CH,OH
The study of the structure and mechanism of DHPS has been accelerated by the recent description of the crystal structures of DHPS from S. aureus and B. coli [17, 26] . The structure of the S. aureus DHPS apoprotein was determined to a resolution of 2.2.4 and the structure of a complex with a substrate analogue, 6-pyrophosphomethyl-pterin, was also determined to 2.4A. The E. coli DHPS structure was determined to a slightly higher resolution, 2.0A, and the structures of a binary complex with DHPPP and a pseudo-ternary complex with 6-hydroxymethyl-7,8-dihydropterin (DHP), pyrophosphate and sulphanilamide were also determined. Both enzyme structures adopt a TIM-barrel type fold, with the active site located at the C-terminal end of the /j-barrel (Figure 2) . A comparison of the alignments of DHPS amino acid sequences from a wide range of sources with both crystal structures reveals some interesting minor differences. For example, DHPS from S. pneuinoniue contains an insertion of approximately 25 amino acids that does not occur in other sequences and appears to fall between the fifth /&strand and fifth x-helix of the TIM barrel. Similarly, the I? falcipai-um gene sequence predicts an insertion of about 30 amino acids between the seventh /&strand and r-helix. The functional significance of these insertions, if any, is unclear at present.
The substrates bind in a cleft that is lined with residues that are highly conserved in all DHPS amino acid sequences. The plane of the pterin ring lies parallel to the axis of the /j-barrel, with the pyrophosphate group pointing outwards. A network of hydrogen bonds from the side chains of residues in the protein is responsible for recognition of the pterin ring. These comprise (in the E. coli numbering scheme) Asp-96, Asn-115, Asp-185 and Lys-221, and are all residues that are absolutely conserved in sequence alignments. Met-139 and Phe-190 may also play an important part in recognition of the pterin ring by forming hydrophobic contacts, and these residues are also highly conserved. Thr-62 plays an important part in the recognition of the ci-phosphate group, with two hydrogen bonds from main chain and side chain atoms. Interest-ingly, this position is occupied by a serine in the I'lasmodiuni dhps amino acid sequence and this portion of the structure is subject to mutation in dlzps sequences from sulphonamide-resistant strains (see below). The j-phosphate group is effectively sandwiched between the side chains of Arg-63 and Arg-255, and additional hydrogen bonds are contributed by Asn-22 and His-257. This elaborate network of hydrogen bonds suggests how pyrophosphate, a product of the reaction, could be recognized independently by the enzyme.
T h e sulphanilamide lies across the outside of the pterin binding cleft and its recognition involves fewer residues than DHPPP. The ligand is surrounded by Arg-63, Pro-64, Arg-220, Lys-221 and His-257, all of which are conserved except Arg-63, which is Asn and Gly in the 'I'oxoplasnza and Plasmodium sequences respectively. One side of the sulphanilamide appears to 
Structure of S. aureus DHPS dimer
The diagram was constructed with Molscript [28] , using the coordinates for S aureus DHPS (PDB accession code IAD I ) be exposed to bulk solvent, which could explain why such a variety of sulphonamide derivatives are effective inhibitors of the enzyme. T h e aniline nitrogen atom on sulphanilamide is located 3.65A from C11 within DHP, the atom that is the target of attack by the nitrogen atom in catalysis. This appears to be too far for a reaction to occur efficiently, although the DHP and DHPPP ligands appear to occupy identical positions in space. As the authors point out, it seems likely that a subtle rearrangement of the relative positions of DHPPP and sulphanilamide is required for catalysis [26] . Indeed, it is noteworthy that the positions of the main chain atoms in the E. coli structure are essentially unchanged in the apoprotein, binary and pseudoternary complexes. In this respect the situation is similar for the S. LULI-~US crystal structure. The structure was determined alone and in complex with the substrate analogue 6-pyrophosphomethyl-pterin: again, there were no significant structural changes on binding of the ligand. The S. aureus crystal structure does differ from the E. roli DHPS in one important respect: electron density arising from the 6-pyrophosphomethylpterin ligand was found in only one monomer of the non-crystallographic dimer, suggesting a half-of-sites reactivity [ 171. Additional evidence for this hypothesis was obtained from steadystate kinetic measurements, which showed substrate inhibition at high concentrations of PABA. The authors proposed a second, non-catalytic, binding site for PABA in S. aureus DHPS which would affect the rate of reaction when occupied. The crystals of the 1;. c d i enzyme contain a monomer in the asymmetric unit and so monomers within the dimer are related by crystallographic symmetry. Occupancy of only one binding site per dimer cannot be observed in this crystal form. Detailed studies of the kinetics of E. coli DHPS have not shown any evidence for substrate inhibition at high concentrations of PABA and DHPPP, although product inhibition studies suggested an ordered binding mechanism, with DHPPP binding first [27] . However, the authors found this scheme difficult to reconcile with the variation of velocity with substrate concentration, which was characteristic of a pingpong reaction scheme. Furthermore, it would appear that the lack of substantial changes in structure on binding of DHPPP, as observed in the E. coli crystal structure, do not agree well with the results o f the kinetic studies.
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It is interesting to examine the distribution of the sulphonamide resistance mutations across the DIIPS structure. Figure 3 shows the location of the five sites of point mutation identified by Wang et al. [lo] that are involved in mediating resistance to sulphonamides in t'lusmodium. T h e mutations fall towards one end of the protein and are generally located close to the sulphanilamide binding site. Thr-62 and Arg-63 form direct contacts with sulphanilamide and DHPPP and it is plausible that mutations in these positions in the I'lusmocfiiim DHPS could directly alter the discrimination between pABA and sulphonamide binding. In the case of the other three sites the equivalent residues in the Z,'. coli structure are [10] [11] [12] [13] [14] [15] removed from the sulphanilamide, suggesting that mutations in these regions may exert an indirect effect, possibly by altering the conformations of the loops that pack around the drug. Some of the mutations occur singly, for example Ser-436Ala (equivalent to position 62 in the E. coli sequence). Others only occur in combination with other mutations, e.g. Ala-581Gly T h e insertions identified by Maskell et al. [23] that appear to cause sulphonamide resistance in the S. pneiimoniur d i p s gene occur between residues Pro-64 to Arg-67 in the E. coli sequence, which are directly opposite Thr-62 and Arg-63 on the other side of a /)-hairpin. It seems plausible that these mutations also exert an indirect effect on sulphonamide binding by changing the conformation of the loop. T h e dipeptide 'SerGly' insertion that appears to contribute to sulphonamide resistance in ,\'. meningitidis occurs in a different part of the structure at Gly-189 in the R. c-oli sequence, in a similar position to one of the Plasmodium mutations (Figure 3) . One of the single site mutations in the A! mrningitidis dhps gene also lies in this region. The situation in the case of the S. uureus enzyme is less clear: sequencing of the dhps genes from several sulphonamide-resistant clinical isolates identified multiple mutations in each isolate that were distributed across the stucture and not localized close to the ligand binding sites. It is unclear at present whether these are all required to confer sulphonamide resistance.
In conclusion, it is clear that the study of DHPS as a drug target has now entered an exciting new phase. Although the enzyme has been known for many years, it is now being revisited with modern molecular biological and biophysical techniques. This has opened up new avenues of possibilities for the rational design of antifolates which were clearly not open to medicinal chemists 60 years ago.
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